Diagnosis of Lung Cancer
Yale University School of Nursing, West Haven, Connecticut, and University of California, San Francisco, California
Authors’ disclosures of potential conflicts of interest are found at the end of this article.
Marianne Davies, DNP, MSN, CNS, ACNP, AOCNP®, Yale University School of Nursing, 400 West Campus Drive, PO Box 27399, West Haven, CT 06516. E-mail: marianne.davies@yale.edu
J Adv Pract Oncol 2017;8:11–23 | https://doi.org/10.6004/jadpro.2017.8.5.12 | © 2017 Harborside Press®
ABSTRACT
Over the past 10 years, there have been significant advances in the diagnosis of lung cancer. Screening of high-risk patients with computed tomography scans and genomic biomarkers aid in the diagnosis of lung cancer patients at earlier stages. Historically, a diagnosis of lung cancer was made solely on histologic classification, usually when patients had advanced-stage disease. Diagnosis has become more precise and patient-centered with the incorporation of immunohistochemistry and genetic analysis for driver mutations utilizing tissue and liquid biopsies. Precise diagnostic classifications influence the prognosis, management, and outcomes of patients with lung cancer. This review will highlight key diagnostic elements essential for the multidisciplinary management of patients with lung cancer.
For access to the full length article, please sign in.